Hybrid contact lens created for keratoconus

Article

SynergEyes Inc. recently introduced a new contact lens (CL) design (ClearKone) for patients with keratoconus.

Key Points

Carlsbad, CA-SynergEyes Inc. recently introduced a new contact lens (CL) design (ClearKone) for patients with keratoconus. The design is optimized to vault the predominant irregularities of the keratoconic cornea, effectively restoring vision to a majority of patients with irregular corneas, according to the company.

The new design uses hybrid technology to make a lens with the visual clarity of a high-oxygen rigid gas permeable CL and the comfort and convenience of a soft lens, according to the company.

"SynergEyes recognized the need to develop a hybrid CL design that could fit a much broader spectrum of keratoconus patients, including oval cones, highly advanced central cones, decentered cones, and-depending on the specifics of the case-globus keratoconus and pellucid marginal degeneration," said Kellie Kaseburg, vice president of global marketing for SynergEyes.

Recent Videos
Katie Rachon, OD, FAAO, Dipl ABO, shares her excitement for the upcoming conference and what it means for an optometrist's toolbox.
EnVision Summit Cochair Cecelia Koetting, OD, FAAO, Dipl ABO, says that attendees should get ready for more discussion-based panels at this year's conference.
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
Bonnie An Henderson in an interview for the EnVision Summit
From new treatments on the horizon for macular degeneration to strengthening comanagement ties, optometrists cite a lot to be excited about in the coming year.
EnVision Summit cofounder and program chair Dr Bonnie Henderson chats about collaborative eye care
Practice owners testify to the importance of trying new things, not being afraid to fail, and utilizing community as a resource when starting up a new practice.
Bonnie An Henderson in an interview for the EnVision Summit
© 2025 MJH Life Sciences

All rights reserved.